Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.

Neal D. Shore

CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwa

BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).

Maha H. A. Hussain

Multi-centre prospective evaluation of cognitive function in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) or enzalutamide (ENZ): The ACE study.

Amit Bahl

Differences in genomic, transcriptomic, and immune landscape of prostate cancer (PCa) based on site of metastasis (mets).

Umang Swami

Survival outcomes for rural patients with advanced prostate cancer: A SEER investigation.

Liang G Qu

ERBB3 expression in racially diverse patients with castration-sensitive prostate cancer and its association with a unique AR activity signature.

Jordan Vellky

Disparities in prostate cancer mortality and clinical trial availability across vulnerable populations.

Rishi Sekar

Evolving trends in prostate cancer: Disparities across income levels and global regions (1990-2019).

Chinmay Jani

The 340B Drug Pricing Program and oral specialty drugs for advanced prostate cancer.

Kassem S Faraj

Impact of race on outcomes to 177Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC).

Avina Rami

Racial and ethnic differences in the receipt of metabolic syndrome risk factor screening and treatment among individuals with prostate cancer treated with androgen deprivation therapy.

Yazan K. Barqawi

Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).

Frederic Pouliot

Total and anatomically contextualized quantitative ¹⁸F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progressionfree survival in patients with prostate cancer.

Hong Song

Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.

Michael Leapman

PSMA PET imaging for evaluation of recurrent or persistent prostate cancer after primary prostate radiation.

Richard Bennett

Differences between whole body magnetic resonance imaging (WB-MRI) and chest/abdomen/pelvis computed tomography (CT)/bone scan (CT/B) in patients staged as having metastatic hormone-sensitive prostate cancer (mHSPC): A retrospective comparative study with

Mona Hassan

Impact of ¹⁸F-flotufolastat PET on management of patients with recurrent prostate cancer: Data from the SPOTLIGHT study.

Przemyslaw Twardowski

Association between SPECT/CT total tumor volume (TTV) and new lesions (NLs) in early cycles of ¹⁷⁷Lu-PSMA-617 (LuPSMA) and progression-free and overall survival (PFS and OS) in men with metastatic castrationresistant prostate cancer (mCRPC).

Ridvan Arda Demirci

Association between PET-based TheraP eligibility and ¹⁷⁷Lu-PSMA-617 (LuPSMA) outcomes in VISION-eligible patients with metastatic castration-resistant prostate cancer (mCRPC).

Ridvan Arda Demirci

Nucleosome profiling at AR binding sites (ARBS) to provide a prognostic tool for metastatic castration-resistant prostate cancer (mCRPC).

Chao Dai

Prostate-specific membrane antigen SPECT-CT in patients with intermediate and high-risk prostate cancer in primary diagnosis: A comparative analysis with ¹⁸F-PSMA PET/CT.

Joel E. Vargas Ahumada

Low- and high-volume disease in mHSPC, from CHAARTED to PSMA-PET: An international multicenter retrospective study.

Lena Unterrainer

Response evaluation criteria in PSMA PET/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer.

Andrei Gafita

Prognostic value of artificial intelligence (AI) –driven tumor estimation of PSMA PET total tumor burden (TTB) in newly diagnosed high-volume metastatic hormone-sensitive prostate cancer (mHSPC).

Francisco Osvaldo Garcia-Perez

Survival and fracture risk with radium-223 therapy in metastatic castrateresistant prostate cancer (mCRPC): A real-world analysis.

Hanbo Zhang

Real-world comparison of prostate-specific antigen (PSA) response in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or enzalutamide (ENZ).

Benjamin H. Lowentritt

Real-world treatment patterns in patients with BRCA 1/2-positive (BRCA+) metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.

Mehmet Asim Bilen

Prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC) initiated on apalutamide (APA) or abiraterone acetate (ABI) in real-world urology practices.

Gordon Andrew Brown

Financial toxicity from PARP inhibitors in castrate-resistant prostate cancer.

David Joseph Benjamin

Real-world treatment (Tx) sequences and time to discontinuation (rwTTD) in the first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) setting.

Emily Nash Smyth

Identifying patient profiles and mapping treatment journeys of ARPItreated, taxane-naive patients with metastatic prostate cancer across three countries in a digital patient survey.

Joe M. O’Sullivan

Real-world survival of men with metastatic castration-sensitive prostate cancer (mCSPC) initiated on apalutamide (APA) or enzalutamide (ENZ) in an oncology database: ROME Study.

Mehmet Asim Bilen

Analysis of real-world survival for patients with metastatic castrationsensitive prostate cancer (mCSPC) treated with apalutamide (APA) or abiraterone acetate (ABI) in an oncology database: ROMA study.

Mehmet Asim Bilen

A real-world observational study characterizing patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with or without androgen receptor pathway inhibitors (ARPIs).

Michael Paul Kolinsky

Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program study.

Robert Bruce Montgomery

Time to next systemic therapy after stereotactic body radiation therapy for oligoprogressive metastatic castrate-resistant prostate cancer.

Corbin J. Eule

Clinical and patient factors associated with treatment intensification for metastatic castration-sensitive prostate cancer.

Sreevalsa Appukkuttan

Real-world economic burden of patients with metastatic castrationsensitive prostate cancer (mCSPC).

Deborah Kaye

Survival Outcomes of APA as a Starting treatment: Impact in real-world patients with mCSPC (OASIS).

Benjamin L. Maughan

Underutilization of androgen deprivation therapy (ADT) intensification for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC): A systematic review of real-world database studies.

Amit D Raval

Effect of prednisone dosing on mineralocorticoid-related side effects with abiraterone in prostate cancer.

Maksym Goryachok

Number of prescription medications and overall survival in veterans with metastatic hormone-sensitive prostate cancer.

Krishny Karunanandaa

Understanding variation in treatment intensification for de novo metastatic castration-sensitive prostate cancer (mCSPC): A population-based cohort study.

Christopher J.D. Wallis

Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy (iADT) with relugolix.

Patrick Campbell

Challenges in patient-centered germline testing delivery for veterans with advanced prostate cancer (APC).

Daniel H Kwon

Does use of apalutamide enhance outcomes in combination with radiotherapy in metastatic hormone-sensitive prostate cancer? A real-world experience from the UK.

Prantik Das

Survival and comorbid diabetes mellitus in metastatic hormone-sensitive prostate cancer.

Priya Baxi

Cardiovascular medications and overall survival in metastatic hormonesensitive prostate cancer.

Kara Ingram

Impact of exposure to clinical trials and standard-of-care therapy in metastatic or recurrent prostate cancer: An update.

Grace G Kim

Real-world outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) and tumors harboring androgen receptor (<i>AR</i>) ligandbinding domain (LBD) mutations.

Tyler F. Stewart

Clinical outcomes with systemic therapy given after progression on prostate specific membrane antigen radioligand therapy (PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Soumaya Labidi

Real-world utilization patterns of radium-223 in metastatic prostate cancer in the United States: An administrative claims database study.

Amit D Raval

Impact of TP53, RB1, and PTEN mutations on overall survival in metastatic prostate cancer: A multi-center study via the Guardian Research Network.

Mohammad Arfat Ganiyani

Real-world clinical outcomes of patients treated with Lu-177-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC): A singleinstitution experience.

Valeria Maldonado Grijalva

Real-world analyses of mortality risk after androgen deprivation therapy initiation in Black vs. White patients with prostate cancer.

Judd W. Moul

Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.

Jian Guan

Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT).

Colin P Bergstrom

Patient outcomes after therapy with ¹⁷⁷Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC): A tertiary center experience.

Meryam Losee

Quality of treatment with targeted agents for advanced prostate cancer by treating specialist.

Kassem S Faraj

A multi-center retrospective cohort study of patients with mCRPC who received lutetium Lu177 vipivotide tetraxetan.

Kunal Desai

Trends in local therapy utilization and survival of patients with de-novo metastatic prostate cancer treated by hormone therapy with or without systemic therapy intensification with chemotherapy.

Siqi Hu

HRR testing and PARPi utilization among patients with metastatic castration resistant prostate cancer treated in the real-world setting.

Anupama Vasudevan

Nonadherence to medications for chronic conditions and risk of nonadherence to androgen receptor signaling inhibitors (ARSIs) in patients with prostate cancer.

Morgan RL Lichtenstein

A cost-effectiveness analysis assessing systemic treatments in metastatic castration-sensitive prostate cancer (mCSPC) by volume of disease.

Syed Arsalan Ahmed Naqvi

Adherence to American Society of Clinical Oncology (ASCO) language of respect (LoR) guidelines in ASCO Annual Meeting prostate cancer (PCa) abstracts.

Regina Barragan-Carrillo

Impact of combined novel hormonal agents on testosterone levels of patients with prostate cancer undergoing treatment with leuprorelin.

Dr. Paulo Sergio Lages

Association of body-mass index (BMI) with age, PSA, and survival in metastatic prostate cancer.

Martin W. Schoen

Real-world genomic testing patterns in patients with prostate cancer.

Dalia Kaakour

Preliminary reliability of the FACT-RNT in standard-of-care Lu-PSMA therapy of metastatic castration-resistant prostate cancer.

Lisa Marie Gudenkauf

Days spent with healthcare contact by patients with metastatic castrateresistant prostate cancer in the last year of life.

Daniel Sentana Lledo

Marijuana use may be associated with reduced prevalence of prostate cancer: A cross-sectional study using the national survey on drug use and health database.

Turab J Mohammed

A study of the association between enzalutamide blood concentrations and adverse events in patients with castration-resistant prostate cancer.

Taro Iguchi

Implementing consultation audio recording applications to improve informed decision-making (IDM) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) eligible for docetaxel.

Daniel H Kwon

A study to evaluate patient benefit/risk preferences for treatment of metastatic prostate cancer (mPC) in Hong Kong: A discrete choice experiment.

Chi-Fai Ng

Patient-reported outcomes (PRO) in patients (pts) with <i>BRCA1/2</i>-altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study.

Dana E. Rathkopf

Safety outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223 following external beam radiation therapy: REASSURE US subset.

A. Oliver Sartor

Apalutamide toxicity and tolerability: A real-world multicentre experience in metastatic hormone-sensitive prostate cancer (MHSPC) in the United Kingdom (UK).

Sindhu Ramamurthy

Association of inherited steroidogenic genotype with body composition changes after androgen signaling inhibition (ASI) in men with biochemical recurrent (BCR), hormone-sensitive prostate cancer (HSPC).

Neha Venkatesh

Patient reported outcomes (PROs) among patients with metastatic castration-resistant prostate cancer (mCRPC) by homologous recombination repair mutations (HRRm) gene clusters: Findings from the phase 3 TALAPRO-2 study cohort 2.

Karim Fizazi

Toxicity-benefit analysis of advanced prostate cancer trials using weighted toxicity scoring.

Jaspreet Kaur Gill

Comparative health-related quality of life (QoL) in metastatic castrationsensitive prostate cancer (mCSPC): A living systematic review.

Rodolfo Garza Morales

Adverse outcomes (AOs) in patients (pts) with metastatic castrationsensitive prostate cancer (mCSPC) treated with intensified androgen deprivation therapy (ADT+).

Nabiel Ali Mir

PRO-WAVE1: Monitoring patient reported outcomes (PROs) in prostate cancer through Wave Health, a novel ePRO health platform.

Diego Cacho

The frequency of use and enrollment impact of patient-centered outcomes in prostate cancer clinical trials.

Madison Krischak

Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT) pretreatment

Ugo De Giorgi

Interaction of age and benefit of treatment intensification in advanced prostate cancer: An aggregate meta-analysis of 14 randomized trials.

Alicia K. Morgans

Effect of concomitant medications on treatment response and survival in de novo metastatic prostate cancer: Secondary analysis of the LATITUDE study.

Soumyajit Roy

Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).

Himisha Beltran

Outcomes, frailty status, and body composition of men with hormonesensitive prostate cancer treated with bicalutamide and dutasteride.

Justin M Lebenthal

PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results.

Arun Azad

Preliminary data from a dose-escalation phase 1 study with HP518, an AR PROTAC degrader: Safety, tolerability, pharmacokinetics (PK), and first assessment of anti-tumor activity in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC

Arun Azad

Long-term outcomes for patients with radiorecurrent prostate cancer treated with salvage combination IMRT and brachytherapy.

Michael J. Dattoli

Differential treatment effect on overall survival (OS) based on early prostatespecific antigen (PSA) response in metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of TITAN trial.

Soumyajit Roy

Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: Sub-analysis from ENABLE for PCa, a multicenter, randomized controlled trial.

Kouji Izumi

Real-life data on [¹⁷⁷Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in France.

Guilhem Roubaud

(ARTO trial-NCT03449719): Role of local treatment after progression in patients with castrate-resistant prostate cancer undergoing first-line abiraterone treatment.

Giulio Francolini

ARTO trial: Overall survival analysis from a randomized phase II trial testing the benefit of adding stereotactic body radiotherapy to abiraterone acetate in patients with oligometastatic castrate-resistant prostate cancer.

Giulio Francolini

The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).

Guo Hongqian

First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Dana E. Rathkopf

Predictors of PSA response to Lu177-PSMA-617 in metastatic castrationresistant prostate cancer.

Rebecca Hassoun

Association of initial adjustment dose of apalutamide with progression to castration-resistant prostate cancer and skin-adverse events in men with metastatic castration-sensitive prostate cancer: Amulticenter retrospective study of CsJUC cohort.

Yoichiro Tohi

Phase II trial of pembrolizumab for patients suffering from metastatic castration resistant prostate cancer (mCRPC) with DNA repair defects, high tumour mutation burden, and/or high CD3 counts (PERSEUS1).

Pasquale Rescigno

Phase 1/2a study of PRL-02, a long-acting IMdepot injection of abiraterone decanoate, in patients with prostate cancer including those previously treated with enzalutamide.

Jose W. Avitia

Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design.

Christos Kyriakopoulos

Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study.

Naoki Fujita

Characteristics and outcomes of patients (pts) with metastatic castrationresistant prostate cancer (mCRPC) treated with lutetium-177–PSMA-617 (PSMA-RLT) in a real-world setting.

David Kersting

Analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with carboplatin-paclitaxel after multiple lines of treatment.

Elisa María Fernández Pérez

Real-world (RW) survival and outcomes with androgen receptor pathway inhibitor (ARPI) –doublet therapy in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC).

Joshua Parrish

Efficacy and safety between first-line therapies in metastatic castrationresistant prostate cancer in combination in the PARPi and ARSI era: A systematic review and network meta-analysis.

Xuanjun Guo

Final study analysis of PRINT: Prostate cancer intensive, non–crossreactive therapy for CRPC.

Bobby Chi-Hung Liaw

Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E.

Marinela Augustin

Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G.

Peter C.C. Fong

Oral cyclophosphamide (Cyc) in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC): A retrospective cohort from a tertiary public cancer center in Brazil.

Yumi Ricucci Shinkado

Radiographic progression without PSA progression in metastatic hormonesensitive prostate cancer (mHSPC): A retrospective analysis from the ENZAMET trial (ANZUP 1304).

Ian D. Davis

Enfortumab vedotin (EV) as monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of stage I of a phase 2 trial.

Umang Swami

Outcomes of elderly patients (pts) treated with docetaxel (DOC) for metastatic castration-sensitive prostate cancer (mCSPC): Results from ECHOS, a multicenter Italian observational study.

Orazio Caffo

Anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with metastatic castration-resistant prostate cancer.

Piotr Jan Wysocki

Effect of camelid B7-H3 tri-specific killer engagers on natural killer cells in patients with prostate cancer.

Nicholas Zorko

Enzalutamide combination treatment (tx) suspension in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK.

Stephen J. Freedland

PSA flare in patients with metastatic castration-resistant prostate cancer undergoing ¹⁷⁷Lu-PSMA treatment.

Haoran Li

Characteristics and outcomes of patients (pts) with metastatic castrationsensitive prostate cancer (mCSPC) showing a primary resistance (PR) to docetaxel (DOC): Results from a large real-world database.

Orazio Caffo

MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results.

Karim Fizazi

Mature results of a phase 2 pilot study of radium-223 and radiotherapy in untreated hormone-naïve menwith oligometastatic prostate cancer to bone.

Jonathan David Tward

Systemic and tumor-directed therapy for oligometastatic prostate cancer (SOLAR): A phase II trial for veterans with de novo oligometastatic prostate cancer.

Nicholas George Nickols

Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial.

Neal D. Shore

The prognostic value of ductal adenocarcinoma of the prostate in patients with advanced prostate cancer treated with abiraterone acetate.

Yifu Shi

Optimal sequential therapy for metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors in the up-front era.

Yushi Naito

Novel dual inhibitors of AR/AR variants and AKR1C3: Preclinical activities for advanced prostate cancer therapy.

Allen Gao

A double-blinded, placebo-controlled, cross-over pilot trial in healthy men to study the effects of <i>Angelica gigas</i> herbal supplement on prostate cancer–relevant inflammatory cytokines.

Anne-Laure Strong

Comparative survival in metastatic castration-sensitive prostate cancer (mCSPC) by prognostic subgroups: A living network meta-analysis.

Syed Arsalan Ahmed Naqvi

First-line PARP inhibitors (PARPi) with androgen receptor pathway inhibitors (ARPi) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and meta-analysis.

Muhammad Ali Khan

Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): Primary endpoint results of a phase II clinical trial.

John Nikitas

Outcomes for patients with mCRPC and liver metastasis receiving 177-Lu-PSMA-617 treatment.

Miguel Muniz

Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki-67.

Fengnian Zhao

Effect of combined treatment with sipuleucel-T and IL-15 on tumor control, tumor-infiltrating immune effectors, and key mediators of immunoresistance in a preclinical prostate cancer model.

Russell Kent Pachynski

The survival outcomes for menwith metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium-223: Princess Margaret Cancer Centre (PMCC) experience.

Esmail M. Al-Ezzi

Somatostatin receptor 1 (<i>SSTR1</i>) expression as a potential predictive biomarker for response to androgen receptor signaling inhibitor (ARSI) therapy in metastatic castration-resistant prostate cancer (mCRPC).

Xiaolin Zhu

Prevalence of HRR mutations in Indian patientswith mCRPC.

Atul Batra

The prognostic value of circulatingmiRNAs in patients with localized/locally advanced prostate cancer after radical prostatectomy and radiotherapy.

Ahmed H. Zedan

A prospective study of comprehensive genomic testing to identify actionable variants in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Daniel Shevrin

Real-world effectiveness of PARP inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) by genomic homologous recombination repair (HRR) alterations and homologous recombination deficiency signature (HRDsig).

Daniel Triner

Tumor suppressor genes (TSG), treatment, and survival in de novo metastatic hormone-sensitive prostate cancer.

Martin W. Schoen

Baseline bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer (mHSPC): Patient-level analysis of SWOG 1216 trial.

Georges Gebrael

Disease characteristics, survival outcomes, and tumor molecular landscape in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) harboring CDK12 alterations (<i>CDK12a</i>) receiving intensified androgen deprivation therapy (ADTi).

Chadi Hage Chehade

Androgen receptor blockade to activate NK cells and to upregulate the surface expression of HLA-E in prostate cancer cell lines.

Maximilian Schwermann

Prognostic value of PSMA-extracellular vesicles in oligometastatic castration-sensitive prostate cancer treated with stereotactic ablative radiotherapy: A multi-center observational study.

Fabrice Lucien

Advancing the drug development process in metastatic prostate cancer through machine learning.

David Alan Quigley

Germline mutations in patients with metastatic prostate cancer: A prospective cohort study in South Korea (KCSG GU20-19).

Joo-Hwan Park

Association of BTN2A1+ microvesicles with overall survival and the role of γδ T cells as a potential therapeutic target in patients with hormone-sensitive metastatic prostate cancer.

Emilien Billon

Genomic mutations and homologous recombination deficiency (HRD) score in Japanese patients with metastatic hormone-sensitive prostate cancer (mHSPC): The impact of intraductal carcinoma of the prostate (IDC-P).

Masashi Kato

Evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) as a value add to PSA in predicting early progression in metastatic castrate resistant prostate cancer (mCRPC).

Christopher Sweeney

Molecular profiling and clinical relevance of low <i>PTEN</i> expression in patients with metastatic hormone-sensitive prostate cancer.

Marta Garcia de Herreros

Detection of neuroendocrine prostate cancer through plasma-based epigenomic profiling.

Marc Eid

Preclinical characterization of human Kallikrein 2 (hK2) as a novel target for the treatment of prostate cancer.

Fei Shen

Association of a prostate cancer gastrointestinal transcriptional phenotype as found in clinical mCRPC samples with response to AR-targeted therapy.

Aishwarya Subramanian

Impact of androgen deprivation therapy (ADT) on circulating tumor DNA (ctDNA) detection in <i>de novo</i> metastatic castration-sensitive prostate cancer (mCSPC).

Edmond Michael Kwan

Characterizing longitudinal molecular changes in ctDNA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Eli Tran

Homologous recombination repair (HRR) alterations may be passenger events in patients with advanced prostate cancer (PC) with high tumor mutational burden (hTMB).

Vineel Bhatlapenumarthi

Men with adrenal-permissive <i>HSD3B1</i> genotype and prostate cancer mortality: Results from the Veterans Affairs Health System Million Veteran Program.

Rana R. McKay

Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results.

Ken Herrmann

11-Ketotestosterone and time to castration resistance in patients with recurrent non-metastatic prostate cancer receiving androgen deprivation therapy.

Chantal Guillemette

Homologous recombination repair gene mutation (HRRm) testing patterns and treatment selection from a real-world cohort of patients with metastatic castration-resistant prostate cancer (mCRPC).

Neal D. Shore

Correlation of PIM kinases with tumor immune microenvironment and clinical presentation of metastatic hormone-sensitive prostate cancer.

Alejandro Recio-Boiles

Evaluation of ctDNA in patients with mCRPC with liver metastases.

Minqi Huang

Dissecting tumor-immune dynamics and radiotherapy response in oligometastatic prostate cancer.

Sophia C. Kamran

Chromatin modifications on plasma ctDNA as a tool to phenotype castration-resistant prostate cancer.

Asli Munzur

The influence of the germline <i>HSD3B1</i> adrenal-permissive variant (c.1100 C) on somatic alteration landscape, transcriptome, and immune-cell infiltration in prostate cancer.

Emmanuel S. Antonarakis

The opposing effects of Class 1B and Class 2 FOXA1 mutations in prostate cancer.

Justin Hwang

Lipidomic profiling as a biomarker for prostate cancer diagnosis and response to enzalutamide (Enza).

Sara Bleve

Effect of variants in the <i>KLK3</i> gene on prostate cancer survival and time to metastases in a large biobank prostate cancer dataset.

Meghana Pagadala

Canonical Wnt signaling pathway (WSP) alterations in metastatic prostate cancer.

Sharon Choi

Cost-effectiveness of triplet therapies in metastatic hormone-sensitive prostate cancer used in PEACE-1 and ARASENS.

Nataniel Hernan Lester-Coll

Estimating median overall survival of apalutamide compared to placebo in metastatic hormone-sensitive prostate cancer (mHSPC) populations: Statistical extrapolations of the TITAN study.

Neeraj Agarwal

Barriers and facilitators to first-line (1L) treatment intensification (TI) in metastatic castration-sensitive prostate cancer (mCSPC): The IMPLEMENT study.

Stacy Loeb

The impact of <i>SPOP</i> gene alterations in menwith metastatic prostate cancer: Results from the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) consortium.

Kyra Lee Yamamoto

Rate of hospitalization and length of hospital stay during and post docetaxel for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS.

Alicia K. Morgans

Trends in preferred place of death for prostate cancer in the United States from 2003 to 2020: Analysis of CDC WONDER database.

Karan Jatwani

EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.

Guillaume Grisay

Clinical study of rezvilutamide inhibiting the flare effect of GnRH agonists in the treatment of newly diagnosed metastatic prostate cancer.

Shaogang Wang

Apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer: A randomized trial (PERSIAN).

Giulio Francolini

Apalutamide (APA) plus intermittent versus continuous androgendeprivation therapy (ADT) in participants (pts) with metastatic castrationsensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design.

Arun Azad

Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor–targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Metastatic castration-resistant prostate cancer cohort.

Susanna Varkey Ulahannan

Peapod FOS trial: A phase 2 clinical trial of pembrolizumab in combination with carboplatin and cabazitaxel in aggressive variant metastatic castration-resistant prostate cancer.

Jorge Esteban Villarrubia

A phase 2 study of cabozantinib and nivolumab in metastatic castrationresistant prostate cancer (CANOPY).

Yu-Wei Chen

A phase 2 single-arm study testing SBRT, adenosine signaling modulation, and immune checkpoint inhibition for men with hormone-sensitive oligometastatic prostate cancer (SBRT-AMICO).

Kristine Peregrino Lacuna

A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.

Evan Y. Yu

LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castrationresistant prostate cancer (mCRPC).

Sumit Kumar Subudhi

ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR).

Andrew Leonard Laccetti

A multicohort phase 2 trial of ADT, docetaxel plus nivolumab in patients with de novo metastatic hormone-sensitive prostate cancer enriched for inflamed tumors and DNA damage repair defects.

Xiao X. Wei

A phase IIa study of sequential ("first strike, second strike") therapies, modeled on evolutionary dynamics of anthropocene extinctions, for highrisk metastatic castration-sensitive prostate cancer.

Jingsong Zhang

SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of ⁶⁷Cu-SAR-bisPSMA in patients with metastatic castrate-resistant prostate cancer.

Geoffrey Johnson

COMBAT: A study of ⁶⁴Cu-SAR-BBN and ⁶⁷Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer.

Luke T. Nordquist

A phase I, open-label, dose-finding study of fatty acid synthase (FASN) inhibitor TVB-2640 administered in combination with enzalutamide (Enza) in men with metastatic castration-resistant prostate cancer (mCRPC).

Pier Vitale Nuzzo

Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.

Evan Y. Yu

Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.

Evan Y. Yu

CaboLu: A phase 1b study of cabozantinib (cabo) in combination with lutetium (Lu 177) vipivotide tetraxetan (LVT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Gliceida Galarza Fortuna

A phase Ib trial of enzalutamide with oral decitabine/cedazuridine in metastatic castration-resistant prostate cancer (CRPC).

Arya Mariam Roy

Safety, tolerability, and dosimetry of ¹⁷⁷Lu-TLX591 with best standard of care in patients with PSMA-expressing metastatic castration-resistant prostate cancer (ProstAct-SELECT).

Nat Lenzo

Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).

Alex Chehrazi-Raffle

A phase II single-arm trial of niraparib in platinum-sensitive metastatic castration-resistant prostate cancer with DNA repair defects (PLATPARP).

Erin Catherine Welch

ProstACT GLOBAL: A phase 3 study of best standard of care with and without ¹⁷⁷Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis dru

Charlotte Hawkins

A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrateresistant prostate cancer and certain other immunologically cold tumors.

Jonathan Alexander Chatzkel

Borxpten: A phase II study of bortezomib (B) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with PTEN deletion.

Vinay Mathew Thomas

Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial.

Christophe Hennequin

Stockholm3 validation in a multi-ethnic cohort for prostate cancer (SEPTA) detection: A multicentered, prospective trial.

Hari Thambiah Vigneswaran

Individual-level social determinants of health and allostatic load/chronic toxic stress in men with prostate cancer.

Nickolas Stabellini

Prostate Cancer Foundation (PCF) screening guidelines for prostate cancer in Black men in the United States.

Isla Garraway

Patient-provider rurality and outcomes in older men with prostate cancer.

Nickolas Stabellini

The effect of dual eligibility on the quality of active surveillance in patients with newly diagnosed prostate cancer.

Kassem S Faraj

Rural-urban disparities in prostate cancer survival: A population-based study.

Siqi Hu

The impact of perceived healthcare discrimination on health outcomes among patients with prostate cancer across racial and ethnic groups.

Daniel Sabater Minarim

Identifying racial disparities in adverse dispositions following major surgery for prostate cancer using machine learning.

Atulya Aman Khosla

A novel blood-based mRNA genomic test for screening, early detection, prognosis, and monitoring of prostate cancer: A multicenter study.

Yutaka Hashimoto

i-Biomarker CaDx: A circulating miRNA-based multi-cancer detection tool with explainable AI for prostate cancer.

Alexandru George Floares

Difference in high-risk prostate cancer detection between transrectal and transperineal fusion approaches.

Sofiya Semko

Contemporary diagnosis of very low risk prostate cancer in a multi-centered hospital system.

Richard Bennett

Diagnosis of prostate cancer and benign prostatic hyperplasia based on urinary cell-free DNA methylation characteristics.

Jindan Luo

Evaluating diagnostic accuracy of the Prostate Imaging after Focal Ablation (PI-FAB) scoring system in detecting clinically significant prostate cancer after primary focal therapy.

David G Gelikman

Assessing the mid-term impact of enhanced prostate cancer screening in Caucasian men with germline DNA repair pathogenic variants.

Massimo Lazzeri

Association between artificial intelligence–derived tumor volume and oncologic outcomes in localized prostate cancer.

David Dewei Yang

Association of multiparametric magnetic resonance imaging findings with oncologic outcomes in non-palpable localized prostate cancer.

Abhishek Kumar

Interim analyses from the PROSPET-BX trial: [^G8Ga]PSMA PET/CT vs. mpMRI in patients with suspicion of prostate cancer and previous negative biopsy.

Egesta Lopci

Predictors of PSMA positivity at initial staging of prostate cancer.

Eric Li

PSMA PET/CT and mpMRI discrepancies in prostate cancer detection with whole-mount histopathology gold standard.

Ida Sonni

Performance of the F-PSMA 1007 PET/CT for high-risk prostate cancer staging: Experience from a Latin American reference center.

Sebastian Peña Rodriguez

Detection and delineation of intraprostatic lesions (IPLs) using multiparametric magnetic resonance imaging (mpMRI) and prostate specific membrane antigen positron emission tomography (PSMA PET) for patients with prostate cancer: A systematic review and m

Aneesh Dhar

Imaging predictive biomarkers of response in patients with prostate cancer undergoing high-intensity focused ultrasound (HIFU) focal therapy.

Egesta Lopci

Association of aggressive prostate cancer features on whole-mount histopathology and quantitative measures on PSMA PET.

Ida Sonni

Prospective evaluation of the Kaiser Permanente prostate cancer risk calculator in biopsy-naïve men with mild PSA elevations.

Joseph Presti

Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer.

John Nikitas

The risk of prostate cancer diagnosis in men with an elevated PSA but low IsoPSA.

Nour Abdallah

Influential factors impacting treatment (tx) decision making (TDM) and decision regret (DR) in patients (pts) with localized or locally advanced prostate cancer (LPC/LAPC).

Benjamin Adam Gartrell

The Capio Prostate Cancer Center model for prostate cancer diagnostics using Stockholm3, MRI, and targeted biopsies: Real-world evidence from 2018 to 2022.

Thorgerdur Palsdottir

Weight variation during androgen deprivation therapy in patients with localized prostate cancer: Data from two prospective randomized trials.

Abdenour Nabid

Contemporary management and pathologic outcomes of men with low- and very low-risk prostate cancer.

Austin Y. Ho

Microboost dose escalation for localized prostate cancer within a statewide radiation oncology quality consortium.

Samuel Regan

Real-world treatment patterns for patients with high-risk biochemically recurrent nonmetastatic castration-sensitive prostate cancer.

Stephen J. Freedland

What criteria do clinicians use to classify men as “high risk” among patients with biochemically recurrent nonmetastatic castration-sensitive prostate cancer?

Stephen J. Freedland

Relugolix versus leuprolide in combination with radiotherapy for localized prostate cancer (REVELUTION trial): An initial analysis of patient treatment preferences and quality of life.

Sagar A. Patel

Urologist practice divestment from radiation vault ownership and treatment patterns for prostate cancer.

Kassem S Faraj

Patients with prostate cancer consider clinical trial options significantly earlier in their journey compared to patients with other solid tumors.

Liat Edry-Botzer

Endocrine and metabolic diseases among survivors of prostate cancer in a population-based cohort.

Siqi Hu

Contemporary androgen deprivation therapy practice patterns in locally advanced prostate cancer treated with definitive radiotherapy: Prospective results from a statewide radiation oncology quality consortium.

Michael Dykstra

Prostate Cancer Supportive Care (PCSC) Program: A model for meeting an unmet need for patients with PC.

Celestia S. Higano

Value-based payment models and management of newly diagnosed prostate cancer.

Avinash Maganty

Hierarchical clustering analysis for predicting 30-day readmissions after major surgery for prostate cancer.

Atulya Aman Khosla

Clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular toxicity from androgen deprivation therapy inmen with prostate cancer.

Sagar A. Patel

A novel cardiovascular disease risk score for prediction of atherosclerotic disease events in men with prostate cancer.

Nickolas Stabellini

Pretreatment colonoscopy impact on acute gastrointestinal (GI) toxicity following curative stereotactic body radiation therapy (SBRT) for localized prostate cancer.

Jonathan W. Lischalk

Impact of a rash management guide on incidence and severity of rash with apalutamide: Experience from the Apa-RP study in high-risk localized prostate cancer.

Neal D. Shore

De novo financial toxicity in patients with prostate cancer following radical prostatectomy and its impact on health-related quality of life.

Thilo Westhofen

Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, singlearm phase II trial.

Junlong Zhuang

Long-term outcomes of a multicenter prospective observational study of active surveillance for early-stage prostate cancer: The PRIAS-JAPAN study.

Takuma Kato

A systematic review: Are the findings of indirect treatment comparisons (ITCs) in metastatic hormone-sensitive prostate cancer (mHSPC) consistent?

Neal D. Shore

Post radical prostatectomy (RP) PSA outcomes following 6 versus 18 months of perioperative androgen receptor signaling inhibitors (ARSI) in men with localized high-risk prostate cancer: Results of Part 2 of a randomized phase 2 trial.

Rana R. McKay

Neoadjuvant pamiparib plus abiraterone and ADT for high-risk/very highrisk localized prostate cancer: Results of a prospective study.

Junlong Zhuang

Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa).

Tamim Niazi

Muscadine grape skin extract in men with biochemically recurrent prostate cancer: A phase III, randomized, multicenter, placebo-controlled clinical trial.

Adel Mandl

Real-world homologous recombination repair mutation (HRRm) testing patterns in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in the United States.

Daniel J. George

Exploring the utility of prostate-derived extracellular vesicles as a urine biomarker for clinically significant prostate cancer.

Ekamjit Singh Deol

Deep learning (DL) algorithms to predict prostate cancer progression on low/intermediate-risk needle core biopsies.

Chien-Kuang Cornelia Ding

Safety and clinical validity of tumor genomic testing for guiding active surveillance selection in men with NCCN intermediate-risk prostate cancer.

Lauren Lenz

Prostate extracellular vesicles and prediction of clinically significant prostate cancer: A prospective single-institution pilot study.

Cameron J Britton

DNA methyl-transferases (DNMTs) as potential therapeutic vulnerability in prostate cancer.

Hari K. Koul

A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy.

Karan Jatwani

PSMA-based PET as an imaging biomarker of androgen receptor signaling in high-risk localized and locally advanced prostate cancer (PCa).

Keara English

Prevalence of variant of unknown significance (VUS) in men with prostate cancer who serve as a benchmark for enhanced screening and for personalized therapy.

Vittorio Fasulo

Utilization of genetic counseling and testing for patients with prostate cancer following integration of a genetic counselor into a genitourinary cancer clinic.

Lindsey Byrne

Comparison of whole slide image–based deep learning algorithms and genomic classifiers for assessing the risk of prostate cancer metastasis in surgically treated patients.

Lia DePaula Oliveira

Comparison of pathologist and deep learning–based prostate cancer grading for prediction of metastatic outcomes in primary prostate cancer.

Lia DePaula Oliveira

SABRE: Assessment of safety and efficacy of ⁶⁴Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.

Luke T. Nordquist

Role of 18F-flotufolastat PET/CT imaging in men with high-risk prostate cancer following conventional imaging and associated changes in medical management: A phase 3b investigator-initiated trial.

Zachariah Taylor

Daro-PET: A phase 2 trial of darolutamide as a prostate-specific membrane antigen (PSMA) expression enhancer in patients with localized prostate cancer.

Jose Mauricio Mota

A randomized, non-comparative, phase II multicentric trial on short-term darolutamide (ODM-201) concomitant to radiation therapy for patients with unfavorable intermediate-risk prostate cancer: DARIUS (AFU-GETUG P15).

Guilhem Roubaud

Phase II trial of ArtemiCoffee for men with biochemical recurrence of prostate cancer after local therapy.

Zin Myint

Phase II study of pembrolizumab in combination with radiation with or without olaparib in localized high-risk prostate cancer.

Zin Myint

A randomized phase I/II study of neoadjuvant treatment with ¹⁷⁷-Lutetium-PSMA-617 with or without ipilimumab in patients with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI trial).

Ulrich Krafft

A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with <i>BRCA1/2</i> gene alterations (NePtune).

Rana R. McKay

SWOG S2210: A phase II study of neoadjuvant carboplatin for localized, high-risk prostate cancer with germline <i>BRCA1/2</i> mutations.

Heather H. Cheng

ASCERTAIN: An open-label, randomized, phase 1, window-of-opportunity study to investigate the biological effects of AZD5305 and darolutamide alone or in combination in men with prostate cancer eligible for radical prostatectomy.

Simon Pacey

Prostate screening for men with inherited risk of developing aggressive prostate cancer: The PATROL study.

Heather H. Cheng

Disparities in the incidence of next-generation sequencing (NGS) among patients (pts) with advanced or metastatic prostate cancer (mPC) and urothelial carcinoma (mUC).

Yeonjung Jo